Induced pluripotent stem cells (iPSCs) hold great promise for basic research and regenerative medicine. They offer the same advantages as embryonic stem cells (ESCs) and moreover new perspectives for personalized medicine. iPSCs can be generated from adult somatic tissues by over-expression of a few defined transcription factors, including Oct4, Sox2, Klf4, and c-myc. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure. The endogenous regenerative potentials of adult hearts are extremely limited and insufficient to compensate for myocardial loss occurring after myocardial infarction. Recent discoveries have demonstrated that iPSCs have the potential to significantly advance future cardiovascular regenerative therapies. Moreover, iPSCs can be generated from somatic cells of patients with genetic basis for their disease. This human iPSC derivates offer tremendous potential for new disease models. This paper reviews current applications of iPSCs in cardiovascular regenerative medicine and discusses progress in modeling cardiovascular diseases using iPSCs-derived cardiac cells.
WongWTSayedNCookeJ.P. Induced pluripotent stem cells: how they will change the practice of cardiovascular medicine. Methodist Debakey Cardiovasc J2013; 9: 206–9.
12.
LiuZZhouJZhaoMWangCh. Current status of induced pluripotent stem cells in cardiac tissue regeneration and engineering. Regen Med Res2013; 1: 6–6.
13.
OhYWeiHMaDSunXLiewR. Clinical application of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart2012; 98: 443–49.
14.
DengW. Induced pluripotent stem cells: path to new medicine. EMBRO Rep2012; 11: 161–5.
15.
SeifinejadATabebordbarMBaharvandHBoyerLSalakdehGH. Progress and promise towards safe induced pluripotent stem cells for therapy. Stem Cell Rev Rep2010; 6: 297–306.
16.
ApostolouEHochedlingerK. iPS cells under attack. Nature2011; 474: 165–6.
17.
ThorrezLSampaolesiM. The future of induced pluripotent stem cells for cardiac therapy and drug development. Curr Pharm Des2011; 17: 3258–70.
ZhangYLiWLaurentTDingS. Small molecules, big roles – the chemical manipulation of stem cell fate and somatic cell reprogramming. J Cell Sci2012; 125: 5609–20.
23.
ZhangRZhangLXieX. iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery. Acta Pharmacol Sin2013; 34: 765–76.
24.
FederationAJBradnerJEMeissnerA. The use of small molecules in somatic-cell reprogramming. Trends Cell Biol2014; 24: 179–87.
25.
HouPLiYZhangXLiuCHGuanJLiHZhaoTYeJYangWLiuKGeJXuJZhangQZhaoYDengH. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science2013; 341: 651–4.
26.
TakhashiKYamanakaS. Induced pluripotent stem cells in medicine and biology. Development2013; 140: 2457–61.
27.
VitaleAMWolvetangEMackay-SimA. Induced pluripotent stem cells: a new technology to study human disease. Int J Biochem Cell Biol2011; 43: 843–6.
28.
AasentTRayaABarreroMJGarretaEConsiglioAGonzalesFVassenaRBilicJPekarikVTiscorniaGEdelMBouéSBelmonteJ. Efficient and rapid generation of induces pluripotent stem cells from human keratinocytes. Nat Biotechnol2008; 26: 1276–84.
29.
SunNPanettaNGuptaDMWilsonKDLeeAJiaFHuSCherrycAMRobbinsdRCLongakerbMTWuJC. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. PNAS2009; 106: 15720–25.
30.
Sanchez-FreireVLeeASHuSAbilezOJLiangPLanFHuberBCOngSGHongWXHuangMWuJC. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells. J Am Coll Cardiol2014; 64: 436–48.
31.
Iglesias-GarcíaOPelachoBPrósperF. Induced pluripotent stem cells as a new strategy for cardiac regeneration and disease modeling. J Mol Cell Cardiol2013; 62: 43–50.
32.
XuHYiBAWuHBockCGuHLuiKOParkJHShaoYRileyAKDomianIJHuEWilletteRLeporeJMeissnerAWangZChienKR. Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature. Cell Res2011; 22: 142–54.
33.
MummeryCLZhangJNgESElliottDAElefantyAGKampTJ. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res2012; 111: 344–58.
34.
MauritzCSchwankeKReppelMNeefSKatsirntakiKMaierLSNguemoFMenkeSHausteinMHeschelerJHasenfussGMartinU. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation2008; 118: 507–17.
35.
Cho GS, Fernandez L, Kwon C. Regenerative medicine for the heart: perspectives on stem-cell therapy. Antioxid Redox Signal. In press.
36.
ZhangJWilsonGFSoerensAGKoonceCHYuJPalecekSPThomsonJAKampTJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res2009; 104: e30–41.
37.
EgashiraTYuasaShFukudaK. Induced pluripotent stem cells in cardiovascular medicine. Stem Cell Int2011, pp. 348960–348960.
38.
SavlaJJNelsonBCPerryCNAdlerED. Induced pluripotent stem cells for the study of cardiovascular disease. J Am Coll Cardiol2014; 64: 512–9.
39.
LianXHsiaoChWilsonGZhuKHazeltineLBAzarinaSMRavalKKZhangJKampTJPalecekSP. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. PNAS2012; 109: E1848–57.
40.
VidarssonHHyllerJSartipyP. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev2010; 6: 108–20.
MalliarasKMakkarRRSmithRRChengKWuEBonowROMarbánLMendizabalACingolaniEJohnstonPVGerstenblithGSchuleriKHLardoACMarbánE. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol2014; 63: 110–22.
47.
RobbersLFNijveldtRBeekAMHirschAvan der LaanAMDelewiRvan der VleutenPATioRATijssenJGHofmanMBPiekJJZijlstraFvan RossumAC.. HEBE Investigators. Cell therapy in reperfused acute myocardial infarction does not improve the recovery of perfusion in the infarcted myocardium: a cardiac MR imaging study. Radiology2014; 272: 113–22.
NelsonTJMartinez-FernandezAYamadaSPerez-TerzicCIkedaYTerzicA. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation2010; 120: 408–16.
50.
MauritzCMartensARojasSVSchnickTRathertCScheckerNMenkeSGlageSZweigerdtRHaverichAMartinUKutschkaI. Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J2011; 32: 2634–41.
51.
TullochNLMuskheliVRazumovaMVKorteFSRegnierMHauchKDPabonLReineckeHMurryCE. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res2011; 109: 47–5.
52.
KawamotoTKobayashiYNakajimaHYamagishiY. Generation of robust vascular networks from cardiovascular blast populations derived from human induced pluripotent stem cells in vivo and ex vivo organ culture system. Biochem Biophys Res Commun2013; 441: 180–85.
53.
KawamuraMMiyagawaSMikiKSaitoAFukushimaSHiguchiTKawamuraTKurataniTDaimonTShimizuTOkanoTSawaY. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation2012; 126: S29–37.
54.
KawamuraMMiyagawaSFukushimaSSaitoAMikiKItoESougawaNKawamuraTDaimonTShimizuTOkanoTTodaKSawaY. Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation2013; 128: S87–94.
55.
TemplinCZweigerdtRSchwankeKOlmerRGhadriJREmmertMYMüllerEKüestSMCohrsSSchibliRKronenPHilbeMReinischAStrunkDHaverichAHoerstrupSLüscherTFKaufmannPALandmesserUMartinU. Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iodide symporter transgene expression. Circulation2012; 126: 430–39.
56.
YangXPabonLMurryCE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res2014; 114: 511–23.
57.
BlazeskiAZhuRHunterDWWeinbergSHZambidisETTungL. Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. Prog Biophys Mol Biol2012; 110: 166–77.
58.
LiangPDuJ. Human induced pluripotent stem cell for modeling cardiovascular diseases. Regenerative Med Res2014; 2: 4–4.
59.
ChowMZBohelerKRLiRA. Human pluripotent stem cell-derived cardiomyocytes for heart regeneration, drug discovery and disease modeling: from the genetic, epigenetic, and tissue modeling perspectives. Stem Cell Res Ther2013; 4: 97–97.
MorettiABellinMWellingAJungCBLamJTBott-FlügelLDornTGoedelAHöhnkeCHofmannFSeyfarthMSinneckerDSchömigALaugwitzKL. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med2010; 363: 1397–409.
62.
VincentGMSchwartzPJDenjoyISwanHBithellCSpazzoliniCCrottiLPiippoKLupoglazoffJ-MVillainEPrioriSGNapolitanoCZhangL. High efficacy of β-blockers in long-QT syndrome type 1. Circulation2009; 119: 215–21.
63.
YazawaMHsuehBJiaXPascaAMBernsteinJAHallmayerJDolmetschRE. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature2011; 471: 230–34.
RefaatMMLubitzSAMakinoSIslamZFrangiskakisJMMehdiHGutmannRZhangMLBloomHLMacRaeCADudleySCShalabyAAWeissRMcNamaraDMLondonBEllinorPT. Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. Heart Rhythm2012; 9: 390–96.
66.
SunNYazawaMLiuJHanLSanchez-FreireVAbilezOJNavarreteEGHuSWangLLeeAPavlovicALinSChenRHajjarRJSnyderMPDolmetschREButteMJAshleyEALongakerMTRobbinsRCWuJC. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med2012; 4: 130ra47–130ra47.
67.
JosowitzRCarvajal-VergaraXLemischkaIRGelbBD. Induced pluripotent stem cell-derived cardiomyocytes as models for genetic cardiovascular disorders. Curr Opin Cardiol2011; 26: 223–9.
